About fezolinetant
Fezolinetant manufacturers are currently limited to the originator, Astellas Pharma, which sells it as Veozah in the US and Veoza in Europe. Fezolinetant is an oral, non-hormonal neurokinin 3 (NK3) receptor antagonist. It reduces moderate to severe hot flashes and night sweats caused by menopause. Since December 2024, its US label carries a boxed warning about rare but serious liver injury. No generic is approved. Pharmaceutical companies can prepare fezolinetant dossiers for launch after patent expiry.
Fezolinetant key facts
|
Property |
Fezolinetant |
|---|---|
|
INN |
Fezolinetant |
|
Molecular formula / weight |
C16H15FN6OS / 358.4 g/mol |
|
ATC code |
G02CX06 |
|
Drug class |
Neurokinin 3 (NK3) receptor antagonist (non-hormonal) |
|
Brand names |
Veozah (US); Veoza (EU) |
|
Originator |
Ogeda; acquired by Astellas in 2017 |
|
Dosage form and strength |
Film-coated tablets 45 mg |
|
Dose |
45 mg once daily |
|
Indication |
Moderate to severe vasomotor symptoms (hot flashes) associated with menopause |
|
First approval |
US FDA, May 2023 |
|
EU approval |
December 2023 |
|
Safety update |
FDA Drug Safety Communication, September 2024; boxed warning for liver injury, December 2024 |
|
Liver testing |
Before starting, monthly for the first 2 months, then at months 3, 6 and 9 (US) |
|
Competitor |
Elinzanetant (Lynkuet, Bayer), a dual NK1/NK3 antagonist approved in the US in October 2025 |
|
Generic status |
None approved |
Fezolinetant manufacturers and licensing history
Fezolinetant was developed by Ogeda, which Astellas acquired in 2017. The FDA approved Veozah in May 2023 as the first non-hormonal NK3 antagonist for menopausal hot flashes. The EU approved it as Veoza in December 2023.
In September 2024, the FDA warned of rare but serious liver injury after a post-marketing case. In December 2024, it added a boxed warning, its strongest warning, and increased the frequency of required liver blood tests. In October 2025, Bayer's elinzanetant (Lynkuet), a related drug, was approved in the US.
No generic fezolinetant is approved. Buyers interested in future generics should confirm the API crystal form, GMP status and freedom to operate.
Fezolinetant dosage forms and dossier types
Fezolinetant is approved as 45 mg film-coated tablets.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Fezolinetant tablets |
45 mg |
Future US ANDA; EU CTD |
Reference Veozah / Veoza |
|
Fezolinetant API |
Bulk |
Future DMF |
Crystal form is critical |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
United States |
Future ANDA |
Patents and new chemical entity exclusivity; boxed warning labelling |
|
European Union |
Future EU CTD |
Data protection and SPC expiry |
|
Other markets |
CTD |
Check local patents |
Fezolinetant regulatory and patent status
The FDA approved fezolinetant in May 2023, and the EU in December 2023. In December 2024, the FDA added a boxed warning for liver injury and stricter liver testing. Fezolinetant is protected by patents and new chemical entity exclusivity, and no generic is approved. Check the FDA Orange Book and national registers before planning development.
Fezolinetant mechanism of action and therapeutic use
After menopause, falling oestrogen levels overactivate KNDy neurons in the brain's temperature control centre, which triggers hot flashes. Fezolinetant blocks NK3 receptors on these neurons and restores temperature control without using hormones. It is taken once daily for moderate to severe menopausal hot flashes, with regular liver blood tests.
Fezolinetant licensing and sourcing
Fezolinetant is currently available only from Astellas. Companies interested in this molecule usually prepare future generic dossiers or API supply. Current offers and supplier contacts are listed among the fezolinetant manufacturers on Pipelinepharma.
Frequently asked questions about fezolinetant
Who manufactures fezolinetant? Astellas makes fezolinetant and sells it as Veozah in the US and Veoza in Europe.
What is fezolinetant used for? Fezolinetant is used for moderate to severe hot flashes caused by menopause.
Does fezolinetant have a safety warning? Yes. Since December 2024, the US label has a boxed warning about rare but serious liver injury, and regular liver blood tests are required.
What forms and strengths of fezolinetant are available? Fezolinetant is available as 45 mg film-coated tablets.
Is there a generic version of fezolinetant? No. No generic fezolinetant is approved.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.